Evaluation of De Novo Donor-Specific Antibodies After Kidney Transplantation: A Single-Center Retrospective Cohort Study From the Debrecen Kidney Transplantation Program.
Abstract
INTRODUCTION Donor-specific antibodies (DSAs) are important biomarkers of humoral alloimmunity and are associated with antibody-mediated rejection and adverse graft outcomes. Allograft survival, the de novo development of DSAs, and subsequent rejection episodes remain the subject of extensive ongoing research. In the present study, we evaluated the impact of perioperative blood transfusion, delayed graft function (DGF), levels of HLA Class I and Class II antibodies, viral infections, prior transplantations, and demographic factors on the development of DSAs and the incidence of ABMR.
Methods
Data from 238 kidney transplantations performed between January 1, 2017, and December 31, 2023, were analyzed retrospectively. The study cohort comprised 62.6% male and 37.4% female recipients (mean age: 54.5 ± 2.3 years for males and 53.8 ± 3.0 years for females). Patients were stratified based on antibody development into a DSA-positive group and a DSA-negative control group. Statistical analyses were performed using the Chi-square test, Fisher's exact test, and logistic regression.
Results
In the DSA-positive group, 17 out of 72 (23.6%) cases involved secondary transplantations (retransplantations), compared to only 8 out of 166 (4.8%) cases in the control group, representing a significant association (P = .001). Perioperative blood transfusions were administered to 42 patients in the DSA-positive group and 58 patients in the DSA-negative group (58.3% and 34.9% respectively, (P = .00099)). DGF was observed in 20 cases within the positive cohort and 21 cases in the negative cohort (27.7% and 12.6% respectively, P = .01). A significant difference was observed regarding the development of ABMR when comparing the presence of HLA Class II antibodies to HLA Class I antibodies (P = .0016). Furthermore, HLA-DR-specific DSAs with high MFI (>5000) were significantly associated with the development of ABMR (P = .031).
Conclusions
The presence of HLA Class II antibodies, particularly those directed against the DR locus, significantly increased the incidence of ABMR. The de novo formation of DSAs can be triggered by several anamnestic clinical factors, such as delayed graft function (DGF), secondary transplantation, and perioperative blood transfusion status as primary risk factors.